References

1. Van Bambeke F, Tulkens PM (2013) The role of solithromycin in the management of bacterial community-acquired pneumonia. Expert Rev Anti Infect Ther 14: 311-324 [CrossRef] [Google Scholar] [PubMed]
2. Farrell DJ, Flamm RK, Sader HS, Jones RN (2016) Results from the Solithromycin International Surveillance Program (2014) Antimicrob Agents Chemother 60: 3662-3668 [CrossRef] [Google Scholar] [PubMed]
3. Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, et al. (2002) The ketolides: a critical review. Drugs 62: 1771–1804 [CrossRef] [PubMed]
4. Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, et al. (2016) Solithromycin: a novel fluoro ketolide for the treatment of communityacquired bacterial pneumonia. Drugs 76:1737-1757 [CrossRef] [Google Scholar] [PubMed]
5. Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, et al. (2010) Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother 54: 4961-4970 [CrossRef] [Google Scholar] [PubMed]
6. Van Bambeke F (2014) Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Ann Med 46: 512- 529 [CrossRef] [Google Scholar] [PubMed]
7. Denis A, Bretin F, Fromentin C, Bonnet A, Piltan G et al. (2000) Betaketo- ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2, 3 enol-ether ketolides. Bioorg Med Chem Lett 10: 2019-2022 [CrossRef] [Google Scholar] [PubMed]
8. Bertrand D, Bertrand S, Neveu E, Fernandes P(2010) Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob Agents Chemother 54: 5399- 5402 [CrossRef] [Google Scholar] [PubMed]
9. Fernandes P, Martens E, Bertrand D, Pereira D (2016) The solithromycin journey-it is all in the chemistry. Bioorg Med Chem 24: 6420-6428 [CrossRef] [Google Scholar] [PubMed]
10. Kannan K, Mankin AS (2011) Macrolide antibiotics in the ribosome exittunnel: species-specific binding and action. Ann N Y Acad Sci 1241: 33-47 [CrossRef] [Google Scholar] [PubMed]
11. Rodgers W, Frazier AD, Champney WS (2013) Solithromycin inhibition ofprotein synthesis and ribosome biogenesis in Staphylococcus aureus,Streptococcus pneumoniae, and Haemophilus influenzae. Antimicrob Agents Chemother 57: 1632-1637 [CrossRef] [Google Scholar] [PubMed]
12. Lemaire S, Van Bambeke F, Tulkens PM (2009) Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in humanTHP-1 macrophages. Antimicrob Agents Chemother 53: 3734-3743 [CrossRef] [Google Scholar] [PubMed]
13. Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P, et al. (2012) Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother 56: 5076-5081 [CrossRef] [Google Scholar] [PubMed]
14. Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, et al. (2013) A novel macrolide solithromycin exerts superior anti-inflammatory effect via NFkappaB inhibition. J Pharmacol Exp Ther 345: 76-84 [CrossRef] [Google Scholar] [PubMed]
15. Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C et al. (2013) A novel macrolide/ fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 169: 1024-1034 [CrossRef] [Google Scholar] [PubMed]
16. Still JG, Schranz J, Degenhardt TP, Scott D, Fernandes P, et al. (2011) Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 55: 1997-2003 [CrossRef] [Google Scholar] [PubMed]
17. Jamieson BD, Ciric S, Fernandes P (2015) Safety and pharmacokinetics of solithromycin in subjects with hepatic impairment. Antimicrob Agents Chemother 59: 4379-4386 [CrossRef] [Google Scholar] [PubMed]
18. Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, et al. (2016) Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial(SOLITAIREORAL). Lancet Infect Dis 16: 421-430 [CrossRef] [Google Scholar] [PubMed]
19. File TM Jr, Rewerska B, Vucinić-Mihailović V, Gonong JRV, Das AF, et al. (2016) A randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-tooral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis 63: 1007-1016